-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*The professional part involved in this article is only for medical professionals to read for reference.
Innovative drugs can quickly relieve flu symptoms.
On April 29, 2021, Roche Pharmaceuticals China announced that its innovative influenza drug Sufuda (generic name: Mabaloxavir) has been formally approved by the National Medical Products Administration of China for the treatment of acute uncomplicated patients aged 12 years and above.
Influenza patients, including those who are at high risk of flu complications.
Mabaloxavir is an innovative cap-shaped structure-dependent endonuclease inhibitor.
It is currently the first and only single-dose oral drug approved for the treatment of influenza.
Mabaloxavir only needs to take the medicine once in the whole course, which can stop the virus detoxification within 24 hours, shorten the infectious period and greatly reduce the duration of flu symptoms, and bring more convenient treatment options for patients.
Influenza is a common acute respiratory infectious disease with serious consequences.
Patients may suffer from complications such as pneumonia, bronchitis, and sinusitis, leading to hospitalization or even death, posing a major threat to public health.
World Health Organization (WHO) data show that, globally, influenza can cause about 5%-10% of adults and 20%-30% of children to infect each year, causing up to 5 million severe cases and 650,000 deaths [ 1-2].
According to a recent study in China, there are an average of 88,000 influenza-related respiratory diseases in excess of death each year in China, which accounts for 8.
2% of the deaths from respiratory diseases [3].
After the patient is infected with influenza, timely and targeted antiviral treatment should be given.
Mabaloxavir, a new major anti-influenza virus drug, can shorten the relief time of influenza symptoms by more than one day with a single oral administration, and has therapeutic benefits for previously healthy influenza patients without underlying diseases and patients at high risk of influenza complications.
.Mabaloxavir is effective for previously healthy people infected with influenza (CAPSTONE-1 clinical trial, people without underlying diseases) and people at high risk of influenza complications (CAPSTONE-2 clinical trial) [4].
Data from the CAPSTONE-1 clinical trial conducted in previously healthy patients with acute uncomplicated influenza showed that mabaloxavir is effective and well tolerated in previously healthy patients.
Compared with placebo, patients taking mabaloxavir can shorten the time to improve symptoms by 26.
5 hours (placebo 80.
2h vs mabaloxavir 53.
7h), and reduce fever by 17.
5 hours (placebo 42h vs mabaloxavir).
Baloxavir 24.
5h).
In the CAPSTONE-2 clinical trial conducted in patients with high risk of influenza complications, mabaloxavir also showed effectiveness and can reduce the occurrence of complications.
Compared with placebo, the time to improve symptoms of high-risk patients taking mabaloxavir can be shortened by 29.
1 hours (placebo 102.
3h vs mabaloxavir 73.
2h).
Zhou Hong, President of Roche Pharmaceuticals China, said: “Under the situation that the global COVID-19 prevention and control situation is still severe, we are very pleased to see the accelerated approval of Mabaloxavir in China.
We hope that this drug with a new mechanism of action, It can effectively help the prevention and treatment of potential large-scale influenza in the winter and spring seasons of influenza, and provide an important supplement to the existing clinical treatment of influenza.
Upholding the concept of'acting on the needs of patients first', Roche will continue to do more in the future.
Innovative products are introduced into China to promote the improvement of the level of disease diagnosis and treatment in the field of anti-infectives, and contribute to China's construction of a strong public health system and better implementation of the "Healthy China 2030" strategy. "References: [1] -to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year.
[3]Li Li YL, Peng Wu, Zhibin Peng, et al.
Influenza-associated excess respiratory Mortality in China, 2010–15: a population-based study[J].
Lancet Public Health 2019, 4: 9.
[4]Ison MG, Portsmouth S, Yoshida Y, et al.
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial [published online ahead of print, 2020 Jun 8].
Lancet Infect Dis.
2020;S1473-3099(20)30004-9 .
doi:10.
1016/S1473-3099(20)30004-9.
Innovative drugs can quickly relieve flu symptoms.
On April 29, 2021, Roche Pharmaceuticals China announced that its innovative influenza drug Sufuda (generic name: Mabaloxavir) has been formally approved by the National Medical Products Administration of China for the treatment of acute uncomplicated patients aged 12 years and above.
Influenza patients, including those who are at high risk of flu complications.
Mabaloxavir is an innovative cap-shaped structure-dependent endonuclease inhibitor.
It is currently the first and only single-dose oral drug approved for the treatment of influenza.
Mabaloxavir only needs to take the medicine once in the whole course, which can stop the virus detoxification within 24 hours, shorten the infectious period and greatly reduce the duration of flu symptoms, and bring more convenient treatment options for patients.
Influenza is a common acute respiratory infectious disease with serious consequences.
Patients may suffer from complications such as pneumonia, bronchitis, and sinusitis, leading to hospitalization or even death, posing a major threat to public health.
World Health Organization (WHO) data show that, globally, influenza can cause about 5%-10% of adults and 20%-30% of children to infect each year, causing up to 5 million severe cases and 650,000 deaths [ 1-2].
According to a recent study in China, there are an average of 88,000 influenza-related respiratory diseases in excess of death each year in China, which accounts for 8.
2% of the deaths from respiratory diseases [3].
After the patient is infected with influenza, timely and targeted antiviral treatment should be given.
Mabaloxavir, a new major anti-influenza virus drug, can shorten the relief time of influenza symptoms by more than one day with a single oral administration, and has therapeutic benefits for previously healthy influenza patients without underlying diseases and patients at high risk of influenza complications.
.Mabaloxavir is effective for previously healthy people infected with influenza (CAPSTONE-1 clinical trial, people without underlying diseases) and people at high risk of influenza complications (CAPSTONE-2 clinical trial) [4].
Data from the CAPSTONE-1 clinical trial conducted in previously healthy patients with acute uncomplicated influenza showed that mabaloxavir is effective and well tolerated in previously healthy patients.
Compared with placebo, patients taking mabaloxavir can shorten the time to improve symptoms by 26.
5 hours (placebo 80.
2h vs mabaloxavir 53.
7h), and reduce fever by 17.
5 hours (placebo 42h vs mabaloxavir).
Baloxavir 24.
5h).
In the CAPSTONE-2 clinical trial conducted in patients with high risk of influenza complications, mabaloxavir also showed effectiveness and can reduce the occurrence of complications.
Compared with placebo, the time to improve symptoms of high-risk patients taking mabaloxavir can be shortened by 29.
1 hours (placebo 102.
3h vs mabaloxavir 73.
2h).
Zhou Hong, President of Roche Pharmaceuticals China, said: “Under the situation that the global COVID-19 prevention and control situation is still severe, we are very pleased to see the accelerated approval of Mabaloxavir in China.
We hope that this drug with a new mechanism of action, It can effectively help the prevention and treatment of potential large-scale influenza in the winter and spring seasons of influenza, and provide an important supplement to the existing clinical treatment of influenza.
Upholding the concept of'acting on the needs of patients first', Roche will continue to do more in the future.
Innovative products are introduced into China to promote the improvement of the level of disease diagnosis and treatment in the field of anti-infectives, and contribute to China's construction of a strong public health system and better implementation of the "Healthy China 2030" strategy. "References: [1] -to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year.
[3]Li Li YL, Peng Wu, Zhibin Peng, et al.
Influenza-associated excess respiratory Mortality in China, 2010–15: a population-based study[J].
Lancet Public Health 2019, 4: 9.
[4]Ison MG, Portsmouth S, Yoshida Y, et al.
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial [published online ahead of print, 2020 Jun 8].
Lancet Infect Dis.
2020;S1473-3099(20)30004-9 .
doi:10.
1016/S1473-3099(20)30004-9.
